AstraZeneca said the additional trial was not likely to delay regulatory approval in Britain and the European Union. LONDON: The head of British drug manufacturer AstraZeneca said on Thursday further research was needed on its COVID-19 vaccine after questions emerged over the protection it offers, but the additional testing is unlikely to affect regulatory approval in Europe.
The head of the Oxford Vaccine Group, Andrew Pollard, said this week that further evidence will be available next month, but the result was still"highly significant". Pfizer/BioNTech's offering requires temperatures of -70 degrees Celsius, driving up costs and potentially making it out of reach for lower and middle-income countries.
"It's always a mistake to make too many judgments early and in particular before the independent regulator has had a chance to look at the results," he told a news conference. "It's also possible that a strong immune response to the first vaccine could effectively block an immune response to the second shot of the same virus."Fletcher's colleague, professor of pharmacoepidemiology Stephen Evans, said speculation about the age distribution in the trials was"not useful to anyone".
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Risk from COVID-19 variants remains after first Pfizer COVID-19 vaccine, UK study findsLONDON :A single dose of Pfizer's coronavirus vaccine may not generate a sufficient immune response to protect against dominant new variants, ... 所以那些還沒有完成接種第二針疫苗的國家是不能對印度，巴基斯坦，尼泊爾，斯里蘭卡開放的。 3rd and 4th doses coming your way. Then 5th and 6th......... WHILE VIRYS MUTATES
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Commentary: Why the Oxford AstraZeneca COVID-19 vaccine is a global game-changerThe Oxford AstraZeneca vaccine may only have an overall effectiveness of 70.4 per cent, but there are other success factors to consider, says an ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
AstraZeneca manufacturing error clouds COVID-19 vaccine study resultsLONDON: AstraZeneca and Oxford University on Wednesday (Nov 25) acknowledged a manufacturing error that is raising questions about preliminary ... Oh dear Lousy
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Philippines to buy 2 million doses of AstraZeneca Covid-19 vaccineMANILA (BLOOMBERG) - The Philippines will sign on Friday an agreement to buy two million doses of Covid-19 vaccine from AstraZeneca Plc.. Read more at straitstimes.com. As long as the vaccine have nothing to do with the CCP regime of China
Source: The Straits Times - 🏆 8. / 63 Read more »
Thailand to sign COVID-19 vaccine agreement with Oxford-AstraZenecaThailand is set to sign a purchase agreement for AstraZeneca's potential COVID-19 vaccine this week, its prime minister said on Thursday, in the ...
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
AstraZeneca says likely to run new global trial on Covid-19 vaccineLONDON (REUTERS) - AstraZeneca is likely to run an additional global trial to assess the efficacy of its Covid-19 vaccine, according to the company's Chief Executive Pascal Soriot, Bloomberg News reported on Thursday (Nov 26).. Read more at straitstimes.com. Is the vaccine really safe?
Source: The Straits Times - 🏆 8. / 63 Read more »